Related Experiment Videos
Urinary hydroxyproline and prognosis in human breast cancer
The British Journal of Surgery
|February 1, 1984
Summary
Urinary hydroxyproline levels do not reliably detect early bone metastases in breast cancer patients. This biomarker showed little value for early bone metastasis detection, even when associated with delayed onset.
Area of Science:
- Biochemistry
- Oncology
- Medical Diagnostics
Background:
- Urinary hydroxyproline is a marker of collagen metabolism.
- Its potential role in detecting bone metastases in breast cancer requires investigation.
Purpose of the Study:
- To evaluate the utility of urinary hydroxyproline excretion for early detection of bone metastases in newly diagnosed breast cancer patients.
Main Methods:
- Measured urinary hydroxyproline and hydroxyproline to creatinine ratio in 342 breast cancer patients before mastectomy.
- Patients were divided into two groups: gelatine-free diet and unrestricted diet.
Main Results:
- Hydroxyproline levels did not correlate with pathological stage or histological grade.
- A significant negative association was found between hydroxyproline excretion and time to bone metastases in patients on a gelatine-free diet.
- No significant difference in hydroxyproline excretion was observed between patients with bone metastases and those without.
Conclusions:
- Urinary hydroxyproline excretion is of limited value for the early detection of bone metastases in breast cancer.
- Dietary factors (gelatine) may influence hydroxyproline levels and their association with disease progression.